Heron Signs LOI with UAE-Based The Node Company to Expand AB-BNCT Cancer Treatment Across GCC Markets

Source：idn news

Heron Signs LOI with UAE-Based The Node Company to Expand AB-BNCT Cancer Treatment Across GCC Markets

 

Heron Neutron Medical Corp. (TWSE: 7799) announced the signing of a Letter of Intent (LOI) with The Node Company, based in the United Arab Emirates (UAE). Together, the two parties will introduce Taiwan’s leading Accelerator-Based Boron Neutron Capture Therapy (AB-BNCT) technology to the Gulf Cooperation Council (GCC) region, targeting one of the fastest-growing healthcare markets in the Middle East. This collaboration is not merely a business partnership; it represents a strategic milestone for Taiwan’s advanced medical technologies entering the Middle Eastern market. 

In recent years, healthcare investment across the GCC region has continued to rise, positioning it as one of the world's most promising healthcare markets. Through this collaboration, The Node Company will serve as a key strategic partner, helping Heron rapidly access core healthcare systems in the UAE and across the GCC while connecting medical institutions and investment resources to accelerate market deployment. This partnership effectively creates a fast-track gateway for Taiwan’s medical innovations into the Middle East’s high-end healthcare sector. 

Leveraging its strong expertise and clinical development momentum in Accelerator-Based Boron Neutron Capture Therapy (AB-BNCT), Heron has established itself as a global leader in advanced cancer treatment technologies. The collaboration extends beyond the introduction of equipment and technology; it encompasses the export of a comprehensive treatment model, including clinical expertise and professional training programs. Together, the partners aim to build a world-class radiation oncology ecosystem centered on Taiwan’s innovation and medical excellence. 

As Middle Eastern governments continue to prioritize healthcare modernization and accelerate the adoption of advanced medical equipment and precision medicine technologies, this strategic partnership creates significant opportunities for Taiwan’s medical industry to expand internationally. Heron emphasized that this initiative is not only about market expansion but also about bringing Taiwan’s healthcare value to the global stage, enabling more patients to benefit from safer and more precise cancer treatment options. 

This collaboration symbolizes Taiwan’s medical technology sector moving from regional leadership to global expansion. By extending its reach beyond Asia and into the core markets of the Middle East, Taiwan can further strengthen its international healthcare presence, enhance the global visibility of its medical brands, and advance the vision of domestically developed healthcare innovation while contributing to the broader goal of a healthier Taiwan.